Evidence map›Paper›PMID 40679635›Full record

ArticleCalcified tissue international2025

Identification of a Novel Gene ARNT2 for Osteogenic Differentiation of Mesenchymal Stem Cells.

Mina Ding, Zhiwei Hu, Ke Pei, Junyuan Hu, Yan Liao, Cheguo Cai, Jian V Zhang

Abstract read
In one paragraph

Article in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mina DingShenzhen Beike Biotechnology Co., Ltd, Shenzhen, 518054, China.
Zhiwei HuShenzhen Beike Biotechnology Co., Ltd, Shenzhen, 518054, China.
Ke PeiShenzhen Beike Biotechnology Co., Ltd, Shenzhen, 518054, China.
Junyuan HuShenzhen Beike Biotechnology Co., Ltd, Shenzhen, 518054, China.
Yan LiaoShenzhen Beike Biotechnology Co., Ltd, Shenzhen, 518054, China. liaoyan@beike.cc.
Cheguo CaiShenzhen Beike Biotechnology Co., Ltd, Shenzhen, 518054, China. cheguo@beike.cc.
Jian V ZhangShenzhen Key Laboratory of Metabolic Health, Shenzhen Metabolism and Reproductive Targeted Delivery Proof-of-Concept Center, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. jian.zhang@siat.ac.cn.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2024A1515010059Basic and Applied Basic Research Foundation of Guangdong Province 2024A1515030277Beike Biotechnology Co., Ltd YF-016National Key R&D Program of China 2024YFA1803001Shenzhen Key Laboratory of Metabolic Health ZDSYS20210427152400001Shenzhen Medical Research Fund B2404004Shenzhen Science and Technology Program JCYJ20220818101218040Shenzhen Science and Technology Program KJZD20230923114504008
6 · The paper itself

Abstract

The balance between adipogenesis and osteogenesis in mesenchymal stem cells (MSCs) is pivotal for the maintenance of bone homeostasis. However, the genes responsible for regulating this balance are still not fully understood. This investigation sought to explore and identify novel genes that influence MSC differentiation into adipogenic and osteogenic lineages, thereby enhancing bone formation. Four datasets from the Gene Expression Omnibus (GEO) database were utilized: three focused on osteogenic differentiation (GSE73087, GSE18043, GSE114117), and one on adipogenic differentiation (GSE37836). Differentially expressed genes (DEGs) during both osteogenic and adipogenic differentiation processes were analyzed using the limma R package. A sum of 471 common differentially expressed genes (CDEGs) were found in MSC osteogenesis, comprising 240 elevated and 231 reduced genes. Similarly, in MSCs adipogenesis, 204 elevated genes and 459 reduced genes were identified. Fourteen hub genes were found to overlap between the CDEGs associated with MSC osteogenesis and DEGs linked to adipogenic differentiation. Notably, the expression of aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) was elevated during osteogenesis but reduced during adipogenesis. Overexpression of ARNT2 enhanced the expression of osteogenic markers in MSCs, while its suppression led to a decrease in osteogenic marker expression. Protein-protein interaction network analysis revealed that ARNT2 interacts with Hypoxia inducible factor 1 subunit alpha (HIF1A), B-cell lymphoma 6 (BCL6), Ubiquitin-specific-processing protease 7 (USP7), and Single-minded homolog 2 (SIM2), which are implicated in the regulation of MSCs osteogenesis. In summary, fourteen hub genes were identified as potential regulators in the osteo-adipogenic differentiation of MSCs. Among them, ARNT2 was confirmed to promote osteogenesis in MSCs and exhibited potential as a therapeutic target for bone-related diseases.

Indexed as

Aryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsCell DifferentiationMesenchymal Stem CellsOsteogenesisAdipogenesisHumansARNT2 protein, humanAryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsARNT2BioinformaticsDifferential expression geneMesenchymal stem cellsOsteogenesis

Identifiers

PMID40679635
PMCPMC12274243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.